Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen

Inclusion Criteria: * Eligible patients will be males or females at least 18 years of age. Women of childbearing potential must have a negative pregnancy test within 10 days prior to randomization into the study. * Patients seropositive for HIV-1 using standard diagnostic criteria. * Patients experiencing inconvenience, toxicity, negative impact on comorbidities or risk of drug-drug interactions with their current regimen * Patients virologically suppressed during at least 12 months prior to inclusion (viral load \<50 copies/mL). * Patients who have signed informed consent to participate in the study. Exclusion Criteria: * Pregnancy, lactation, or planned pregnancy during the study period. * Previous failure to an integrase inhibitor-containing regimen. * Previous failure to a Lamivudine or Emtricitabine-containing regimen. * Resistance mutations to Lamivudine or integrase inhibitor if any resistance test had been previously performed. * Any disease or history of disease which, in the opinion of the investigator, might confound the results of the study or pose additional risk to patient treatment. * Chronic hepatitis B.